Taxonomy
CMTA Announces Strategic Partnership with Acceleron to Advance CMT Treatment Options
"We are excited to establish this partnership with Acceleron as they work to advance their lead neuromuscular therapeutic candidate, ACE-083, through an ongoing Phase 2 trial in patients with CMT," said CMTA's CEO Amy Gray.Volunteer Spotlight: Amy Keller
Amy Keller had always known about CMT as it runs in her family. But, as a healthy, active child who grew up into a symptom-free adult, it had never crossed her mind that she, too, would one day receive that same diagnosis.The CMTA Announces the Funding of a New Research Study for CMT2A
The CMTA announces the funding of a clinical research study that will look at pulmonary function for people who have CMT Type 2A, with the aim of developing a night-time breathing treatment similar to CPAP for CMT2A patients.STAR Launches Research for CMT4C
Completely funded by the CMTA, the 18-month project headed by Dr. Kleopas A. Kleopa of the Cyprus Institute of Neurology and Genetics will explore the possibility of using gene editing to treat CMT4C.PSA on Charcot-Marie-Tooth Disease
The CMTA is thrilled to announce the release of our latest professionally produced Public Service Announcement on Charcot-Marie-Tooth! Watch this beautiful piece and share it with your friends and family to spread the word.NYSCF and CMTA Announce Largest-Ever Research Resource for Neuropathy Disorders
The NYSCF Research Institute and the CMTA announced that the stem cell lines resulting from a collaboration that began in 2014 will now be available for use by other researchers in the largest and first-ever initiative of its kind.New Mobile App Simplifies Sign-Up for Patient Registry
A new mobile app developed by the Rare Diseases Clinical Research Network (RDCRN) makes it easier than ever for CMT patients to sign up for and navigate the network’s patient registry, which will play a key role in identifying patients for clinical trials.New CEO Takes Helm of the CMTA
The CMTA Board of Directors announced May 15 the appointment of Amy J. Gray as the new chief executive officer of the Charcot-Marie-Tooth Association. MDA and CMTA Partner to Advance Treatments and Care for Charcot-Marie-Tooth Disease
The MDA and the CMTA have formed a partnership aimed at advancing CMT research, therapy development and clinical care, while also increasing awareness and understanding of CMT by improving education for patients, medical professionals and the public.MDA and CMTA Fund Grant to Study Gene Therapy in Charcot-Marie-Tooth Disease
The MDA and the CMTA today announced a research grant totaling $119,999 to Kleopas Kleopa, MD, for a study on the effectiveness of a gene therapy approach in the second most common form of Charcot-Marie-Tooth disease (CMT).
